Skip to main content
logo
Mirion Technologies, Inc. (MIR)
NYSE: MIR · Real-Time Price · USD
19.69
+0.25 (1.29%)
At close: Mar 19, 2026, 4:00 PM EDT
19.67
-0.02 (-0.10%)
Pre-market: Mar 20, 2026, 8:00 AM EDT

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Cancer Care Revenue
237.00M228.10M
Cancer Care Revenue Growth
3.90%5.65%
Other Medical Revenue
73.80M71.60M
Other Medical Revenue Growth
3.07%4.37%
Total Medical Revenue
310.80M299.70M
Total Medical Revenue Growth
3.70%5.34%
Nuclear Revenue
374.60M316.60M
Nuclear Revenue Growth
18.32%8.50%
Labs and Research Revenue
122.20M131.70M
Labs and Research Revenue Growth
-7.21%7.16%
Other Nuclear & Safety Revenue
117.80M112.80M
Other Nuclear & Safety Revenue Growth
4.43%10.91%
Total Nuclear & Safety Revenue
614.60M561.10M
Total Nuclear & Safety Revenue Growth
9.54%8.66%
Revenue (Total)
925.40M860.80M
Revenue (Total) Growth
7.51%7.48%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
North America Revenue
582.20M542.20M
North America Revenue Growth
7.38%5.84%
Europe Revenue
327.60M305.60M
Europe Revenue Growth
7.20%12.31%
Asia Pacific Revenue
15.60M13.00M
Asia Pacific Revenue Growth
20.00%-21.21%
Revenue (Total)
925.40M860.80M
Revenue (Total) Growth
7.51%7.48%

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Product Revenue
690.60M643.10M
Product Revenue Growth
7.39%7.58%
Service Revenue
234.80M217.70M
Service Revenue Growth
7.85%7.19%
Revenue (Total)
925.40M860.80M
Revenue (Total) Growth
7.51%7.48%

Adjusted EBITDA

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Medical Adjusted EBITDA
116.40M104.60M
Medical Adjusted EBITDA Growth
11.28%7.28%
Nuclear & Safety Adjusted EBITDA
177.70M159.80M
Nuclear & Safety Adjusted EBITDA Growth
11.20%18.02%
Corporate & Other Adjusted EBITDA
-66.20M-60.80M
Operating Income (Total)
51.50M24.80M
Operating Income (Total) Growth
107.66%-

EBIT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Medical Income from Operations
46.90M22.30M
Medical Income from Operations Growth
110.31%71.54%
Nuclear & Safety Income from Operations
101.10M78.90M
Nuclear & Safety Income from Operations Growth
28.14%71.52%
Corporate & Other Income from Operations
-96.50M-76.40M
Operating Income (Total)
51.50M24.80M
Operating Income (Total) Growth
107.66%-

Capital Expenditures

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Medical Capital Expenditures
20.20M27.80M
Medical Capital Expenditures Growth
-27.34%27.52%
Nuclear & Safety Capital Expenditures
18.70M17.70M
Nuclear & Safety Capital Expenditures Growth
5.65%-1.67%
Corporate & Other Capital Expenditures
700.00K3.30M
Corporate & Other Capital Expenditures Growth
-78.79%230.00%

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Remaining Performance Obligations (RPO)
1.10B811.90M
Remaining Performance Obligations (RPO) Growth
36.01%-5.27%
Remaining Performance Obligations (RPO) to be Recognized Over NTM
49.00%54.00%
Order Book
1.03B843.00M
Order Book Growth
22.42%-7.26%
Medical - Organic Revenue Growth
3.10%2.60%
Nuclear & Safety - Organic Revenue Growth
4.40%8.80%
Total Organic Revenue Growth
3.90%6.60%
Updated Dec 31, 2025. Data Source: Fiscal.ai.